In this Issue:
Over the past decade, a drug called rapamycin has shown promise in extending life by delaying the onset of aging-related diseases such as cancer, heart disease, and Alzheimer’s disease, and also postponing the effects of normal aging. Novartis, the $260 billion Swiss pharmaceutical giant, has begun taking the first steps to position its version of rapamycin, Afinitor, as the first true anti-aging drug. Take a look for yourself.
Get every issue of Bloomberg Businessweek Magazine and unlimited access to over 140 top magazines in one app, including back issues. Try Free at NextIssue.com
About Bloomberg Businessweek Magazine:
The Bloomberg Businessweek Magazine provides you with an in-depth analysis on global business, finance and economy. Latest options, informaton and opinions about all the happenings in the ever-changing world of business.
About Next Issue:
Next Issue allows you to access to over 140 of the world best digital magazines. Get unlimited access to your favorite magazines including back issues anytime, anywhere using our app